20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...
19:10 , Oct 26, 2018 |  BC Week In Review  |  Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...
20:03 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7 agonist tool compound decreased airway resistance and dynamic...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BNC210: Phase II data

Top-line data from the double-blind, placebo- and lorazepam-controlled, 4-way crossover, U.K. Phase II BNC210.006 trial in 24 patients with untreated GAD showed that a single oral dose of 300 mg BNC210 met the co-primary endpoints...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences, Attenua deal

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

BNC210: Completed Phase II enrollment

Bionomics completed enrollment of 24 patients in a double-blind, 4-way crossover, U.K. Phase II trial comparing 300 and 2,000 mg oral BNC210 vs. placebo or lorazepam. Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia   Product: BNC210...